Worldwide Licensing Agreements and Stock Price Movements in HealthCare Companies - Research Report on Baxter, ResMed, PAREXEL,

    Worldwide Licensing Agreements and Stock Price Movements in HealthCare
Companies - Research Report on Baxter, ResMed, PAREXEL, The Cooper Companies,
                                 and Thoratec

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 22, 2013

NEW YORK, November 22, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Baxter
International Inc. (NYSE: BAX), ResMed Inc. (NYSE: RMD), PAREXEL International
Corporation (NASDAQ: PRXL), The Cooper Companies, Inc. (NYSE: COO), and
Thoratec Corporation (NASDAQ: THOR). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Baxter International Inc. Research Report 

On November 15, 2013, Baxter International Inc. (Baxter) and Cell
Therapeutics, Inc. (CTI) jointly announced an exclusive worldwide licensing
agreement to develop and commercialize pacritinib - a novel investigational
JAK2/FLT3 inhibitor with activity against genetic mutations linked to
myelofibrosis, leukemia and certain solid tumors. The companies said that
pacritinib is currently in Phase III development for patients with
myelofibrosis, a chronic malignant bone marrow disorder. Under the terms of
agreement, Baxter gains exclusive commercialization rights for all indications
for pacritinib outside the United States, while Baxter and CTI will together
commercialize pacritinib in the United States. "We believe Baxter represents
the ideal strategic partner to achieve the full potential of pacritinib," said
James A. Bianco, M.D., President and CEO of CTI. "Our two companies share a
dedication to oncology and a vision for bringing this unique oral JAK2/FLT3
inhibitor to patients with certain blood cancers and solid tumors. This
collaboration will provide additional financial resources and commercial
expertise to position us to pursue the development, commercialization and
market potential of pacritinib." The Full Research Report on Baxter
International Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/163d_BAX

--

ResMed Inc. Research Report 

On November 19, 2013, ResMed Inc.'s (ResMed) shares rose 0.32% to end the
trading session at $50.89. Shares of ResMed slipped 1.18% over the past three
trading sessions, while the Dow Jones Industrial Average Index rose 0.57%
during the same period. The Full Research Report on ResMed Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/bd44_RMD

--

PAREXEL International Corporation Research Report

On November 19, 2013, shares of PAREXEL International Corporation (PAREXEL)
dropped 1.76% to end the day at $41.41. Over the previous three trading
sessions, PAREXEL's shares dropped 5.67% as compared to the Dow Jones
Industrial Average Index, which rose 0.57% during the same period. Full
Research Report on PAREXEL International Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/067b_PRXL

--

The Cooper Companies, Inc. Research Report 

On November 19, 2013, shares of The Cooper Companies, Inc. (The Copper
Companies) dipped 0.03% to end the trading session at $127.96. Shares of the
Company rose 0.77% over the past three trading sessions, while the Dow Jones
Industrial Average Index rose 0.57% during the same period. The Full Research
Report on The Cooper Companies, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/9cde_COO

--

Thoratec Corporation Research Report

On November 19, 2013, shares of Thoratec Corporation (Thoratec) dropped 1.64%
to end the trading session at $41.99. Thoratec's shares dropped 2.39% over the
three previous trading sessions, while the NASDAQ composite Index dropped
1.04% during the same period. The Full Research Report on Thoratec Corporation
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1bee_THOR

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.